This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1 DS Wald , M Law & JK Morris (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325, 1202–1206.
2Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288, 2015–2022.
3 LE Bautista , IA Arenas , A Penuela , (2002) Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. J Clin Epidemiol 55, 882–887.
4 S Dayal & SR Lentz (2008) Murine models of hyperhomocysteinemia and their vascular phenotypes. Arterioscler Thromb Vasc Biol 28, 1596–1605.
5 JF Toole , MR Malinow , LE Chambless , (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291, 565–575.
6 KH Bønaa , I Njølstad , PM Ueland , (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354, 1578–1588.
8 Q Yang , LD Botto , JD Erickson , (2006) Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 113, 1335–1343.
9 X Wang , X Qin , H Demirtas , (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369, 1876–1882.
10 JD Spence (2006) Homocysteine. Call off the funeral. Stroke 37, 282–283.
11 KB Holven , P Aukrust , T Holm , (2002) Folic acid treatment reduces chemokine release from peripheral blood mononuclear cells in hyperhomocysteinemic subjects. Arterioscler Thromb Vasc Biol 22, 699–703.
12 KB Holven , P Aukrust , K Retterstøl , (2006) Increased levels of high-sensitivity C-reactive protein and interleukin-6 in hyperhomocysteinemic subjects. Scand J Clin Lab Invest 66, 45–54.
13 KB Holven , B Halvorsen , V Bjerkeli , (2006) Impaired inhibitory effect of interleukin-10 on the balance between matrix metalloproteinase-9 and its inhibitor in mononuclear cells from hyperhomocysteinemic subjects. Stroke 37, 1731–1736.
14 M Arnadottir , B Hultberg , P Nilsson-Ehle , (1996) The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 56, 41–46.
15 C Lewerin , S Ljungman & H Nilsson-Ehle (2007) Glomerular filtration rate as measured by serum cystatin C is an important determinant of plasma homocysteine and serum methylmalonic acid in the elderly. J Intern Med 261, 65–67.
16 J Liu , GK Sukhova , JS Sun , (2004) Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 24, 1359–1366.
17 GK Sukhova , B Wang , P Libby , (2005) Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice. Circ Res 96, 368–375.
19 GP Shi , GK Sukhova , A Grubb , (1999) Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 104, 1191–1197.
20 MA Albert , N Rifai & PM Ridker (2001) Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis. Vasc Med 6, 145–149.
21 L Djoussé , T Kurth & JM Gaziano (2008) Cystatin C and risk of heart failure in the Physicians' Health Study (PHS). Am Heart J 155, 82–86.
22 W Koenig , D Twardella , H Brenner , (2005) Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 51, 321–327.
23 L Ni , J Lü , LB Hou , (2007) Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese. Stroke 38, 3287–3288.
24 DM Maahs , LG Ogden , A Kretowski , (2007) Serum cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes. Diabetes 56, 2774–2779.
25 J Arpegård , J Ostergren , U de Faire , (2008) Cystatin C – a marker of peripheral atherosclerotic disease? Atherosclerosis 199, 397–401.
26 A Bökenkamp , S Herget-Rosenthal & R Bökenkamp (2008) Cystatin C, kidney function and cardiovascular disease. Pediatr Nephrol 21, 1223–1230.
27 MS Nenseter , T Ueland , K Retterstøl , (2009) Dysregulated RANK ligand/RANK axis in hyperhomocysteinemic subjects. Effect of treatment with B-vitamins. Stroke 40, 241–247.
28 KB Holven , B Halvorsen , H Schulz , (2003) Expression of matrix metalloproteinase-9 in mononuclear cells of hyperhomocysteinaemic subjects. Eur J Clin Invest 33, 555–560.
29 E Bengtsson , F To , A Grubb , (2005) Absence of the protease inhibitor cystatin C in inflammatory cells results in larger plaque area in plaque regression of apoE-deficient mice. Atherosclerosis 180, 45–53.
30 S Yap , GH Boers , B Wilcken , (2001) Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol 21, 2080–2085.
31 C Keller , R Katz , M Cushman , (2008) Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol 9, 9.
32 CR Keller , MC Odden , LF Fried , (2007) Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study. Kidney Int 71, 239–244.
33 D Singh , MA Whooley , JH Ix , (2007) Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol Dial Transplant 22, 1087–1092.
34 K Potter , GJ Hankey , DJ Green , (2008) Homocysteine or renal impairment: which is the real cardiovascular risk factor? Arterioscler Thromb Vasc Biol 28, 1158–1164.